EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial

Bradley A Edwards iD, Luke D J Thomson iD, Daniel Vena iD, Andrew Gikas, Reza Radmand, Nicole Calianese, Lauren B Hess, Jinny Collet, Dillon Gilbertson, Natalie V Lawrence, Shane A Landry iD, Simon A Joosten iD und 3 weitere

European Respiratory Journal · 2026

DOI: 10.1183/13993003.01320-2025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2026. Verfasst von Bradley A Edwards und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Biomedical Discovery Institute, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Mandibular Advancement, Oxygen, Oxygen Inhalation Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment for obstructive sleep apnoea (OSA) is limited by intolerance to continuous positive airway pressure. While OSA manifests due to both increased pharyngeal collapsibility and ventilatory control instability, randomised trials targeting both components are lacking. We tested whether combining a ventilatory control intervention (supplemental oxygen) with an upper airway mechanical intervention (mandibular advancement device (MAD)) improves treatment efficacy.

Methods

In a multicentre randomised crossover trial, 41 patients with moderate-to-severe OSA (apnoea–hypopnoea index (AHI) >20 events·h −1 , scored without desaturation criteria) underwent polysomnography with four single-night interventions: oxygen (4 L·min −1 ), MAD, combination therapy and sham (air). Primary analysis compared percent change in AHI from baseline between combination therapy and MAD monotherapy. Secondary outcomes included arousal index and visual analogue scale for sleep quality (VASSQ). Gold standard baseline pathophysiological traits facilitated mechanistic subgroup analysis.

Results

Of 41 randomised patients (14 females:27 males, median (interquartile range) baseline AHI 49 (29, 62) events·h −1 ), 38 completed all interventions. Compared with sham, AHI was lowered with oxygen (estimate: −33 (95% CI −46, −17)%), MAD (−54 (95% CI −64, −41)%) and the combination (−68 (95% CI −77, −57)%); the combination provided a greater reduction than MAD monotherapy (−14 (95% CI −23, −4)%; p=0.009). The combination also improved AHI per 3% desaturation/arousal criteria (−73 (95% CI −81, −62)% versus sham and −17 (95% CI −25, −7)% versus MAD). The combination improved arousal index (−36 (95% CI −43, −27)% versus sham) and VASSQ (+0.98 (95% CI 0.39, 1.58) versus sham), albeit not significantly beyond MAD alone. Effects were greatest in those with higher loop gain and collapsibility.

Conclusion

Combining a ventilatory control intervention (supplemental oxygen) with an upper airway intervention (MAD) is a promising approach to markedly attenuate OSA severity beyond that offered by each intervention alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveMandibular AdvancementOxygenOxygen Inhalation TherapyHumansMaleFemaleMiddle AgedCross-Over StudiesPolysomnographyAdultTreatment OutcomeCombined Modality TherapyContinuous Positive Airway PressureSleep QualityAged

Substanzen

Oxygen

Autor:innen und Institutionen

  • Department of Physiology, Biomedical Discovery Institute, Monash University, Melbourne, Australia.
  • School of Psychological Sciences, Monash University, Melbourne, Australia.
  • Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Melbourne Teaching Health Clinics, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Australia.
  • Dental Services, The Alfred, Melbourne, Australia.
  • Monash Lung and Sleep, Monash Medical Centre, Clayton, Australia.

ORCID-Profile: Bradley A Edwards, Luke D J Thomson, Daniel Vena, Shane A Landry, Simon A Joosten, Garun S Hamilton, Scott A Sands

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • American Heart Association
  • National Heart Foundation of Australia
  • Monash Lung and Sleep Institute

Zitieren

APA

Edwards, B. A., Thomson, L. D. J., Vena, D., Gikas, A., Radmand, R., Calianese, N., Hess, L. B., Collet, J., Gilbertson, D., Lawrence, N. V., Landry, S. A., Joosten, S. A., Hamilton, G. S., Wellman, A., & Sands, S. A. (2026). Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial. European Respiratory Journal. https://doi.org/10.1183/13993003.01320-2025

Vancouver

Edwards BA, Thomson LDJ, Vena D, Gikas A, Radmand R, Calianese N, et al. Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial. European Respiratory Journal. 2026. doi:10.1183/13993003.01320-2025

BibTeX
@article{Edwards2026,
  author = {Edwards, Bradley A and Thomson, Luke D J and Vena, Daniel and Gikas, Andrew and Radmand, Reza and Calianese, Nicole and Hess, Lauren B and Collet, Jinny and Gilbertson, Dillon and Lawrence, Natalie V and Landry, Shane A and Joosten, Simon A and Hamilton, Garun S and Wellman, Andrew and Sands, Scott A},
  title = {Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial},
  journal = {European Respiratory Journal},
  year = {2026},
  doi = {10.1183/13993003.01320-2025}
}
Kostenlos starten →